Introduction
Regulatory data exclusivity and market exclusivity are fundamental components of the European Union (EU) pharmaceutical framework, providing medicine developers with periods of protection that support innovation, investment, and the development of new therapies. These protections are particularly important in enabling pharmaceutical and biotechnology companies to recover the significant costs associated with research, clinical development, and regulatory approval.
As part of the proposed revision to the EU pharmaceutical legislation, the framework governing regulatory data protection and market exclusivity is expected to undergo substantial reform. The new legislation aims to balance innovation incentives with improved patient access to medicines across Member States, introducing changes to exclusivity periods and additional conditional extensions linked to unmet medical need, comparative clinical data, and product availability throughout the EU.
In this blog, we explore the current EU framework for regulatory data exclusivity and market exclusivity, examine the proposed legislative changes, and discuss what these reforms could mean for pharmaceutical and biotechnology companies developing medicines in Europe.
The new pharmaceutical regulation
In April 2023, the European Union (EU) undertook a comprehensive evaluation of the pharmaceutical legislation. It adopted a proposal for a new pharmaceutical Directive (2023/0132)1 and a new Regulation (2023/0131)2, which revise and replace the existing general pharmaceutical legislation (Directive 2001/83/EC3 and Regulation (EC) No 726/20044). This evaluation also included a proposal to repeal the existing Orphan Medicinal Products Regulation (EC) No 141/20005, and the Paediatric Regulation (EC) No 1901/20066 and to identify strengths and areas for improvement in a new regulation.
On the 11th of December 2025, the EMA announced that the European Parliament and the Council of the European Union reached a political agreement on the reform of the EU pharmaceutical legislation. It is now undergoing a formal review by the European Parliament and the Council.
To learn more about EU pre-approval regulatory requirements, marketing authorisation applications, and the impact of the revised pharmaceutical legislation on medicine development, watch our webinar: ‘Future-proofing your EU regulatory deliverables and the impact of the revised pharmaceutical legislation on medicine development’.
Regulatory data and market protections
What is regulatory data exclusivity?
In line with the current Directive 2001/83/EC3 and Regulation (EC) No 726/2004,4 a company hoping to develop a hybrid, generic or biosimilar product cannot refer to or rely on the reference medicinal product’s MAA dossier to gain MA for a set time.
This is known as ‘data exclusivity’ and is enforceable for 8 years from when the reference medicinal product was granted MA.4
What is drug market exclusivity?
Alongside the 8-year data exclusivity period, the reference medicinal product is also protected from any hybrid, generic or biosimilar product being placed on the market, even if you have submitted to and received a positive opinion from the EMA on your MAA.
Marketing exclusivity applies for 10 years from when the reference medicinal product was granted MA.4
Current extensions to market protection
Per Article 14(11) of Regulation (EC) No 726/2004,4 data exclusivity and market protection of a reference medicinal product may be extended by 1 year (11 years of market protection in total) if, in the first 8 years, the MA holder receives authorisation for one or more new indications.
In total, the current regulatory data protection lasts 8 years. Market exclusivity lasts 2 years, giving a total of 10 years of data and market protection. An additional 1 year of market exclusivity can be granted for a new indication.3-4
We have written a blog delving into the current regulatory data and market protections in detail. You can read it here: What are regulatory data and market exclusivity? Drug Approval in Europe.
How will the new pharmaceutical legislation change regulatory data and market protection?
In short, the regulatory data and market protection specifications will become more complicated. Per Article 80 of the revised Directive,1 regulatory data protection shall cover 8 years from the date of the MA being granted, with priority antimicrobials having one additional year of data protection (Article 41 (1) of the revised Regulation).2 After the expiry of the regulatory data protection period, a generic, biosimilar or hybrid cannot be placed on the market for an additional year (regulatory market protection period)2.
This market protection period can be extended by 12 months if the medicinal product addresses an unmet medical need; clinical trials have used a relevant comparator; the EU MAA has been submitted promptly; and trials have been conducted in more than one EU member state.
The regulatory market protection can be extended by an additional year for a new
therapeutic indications which are held to bring a significant clinical benefit in comparison with existing therapies if granted during the regulatory data protection period. This extension may only be granted once.
The current “8+2(+1)” model is replaced by a more flexible and incentive-based system.3-4 The new framework sets a maximum of 8 years of regulatory data protection and three years of regulatory market protection (the ‘8+1(+1+1)’ rule).1-2 Essentially, the regulatory strategy will become significantly more complex and require longer-term planning around the conduct of clinical studies in the EU, use of relevant comparators, earlier submission of EU marketing applications and lifecycle planning for new indications.
Summary
The proposed revision to the EU pharmaceutical legislation is expected to significantly reshape the framework for regulatory data exclusivity and market exclusivity in Europe. Changes to baseline protection periods and the introduction of conditional exclusivity extensions may alter how pharmaceutical and biotechnology companies approach development strategy, product launch planning, and lifecycle management within the EU market.
For medicine developers, understanding these evolving exclusivity frameworks as a result of the revised pharmaceutical legislation will be critical for effective regulatory and commercial planning.
How Somerville Development Partners can help
Our team brings decades of combined experience across both consultancy and industry settings. This dual perspective enables us to balance regulatory rigour with scientific and operational realities.
We don’t just advise, we embed within your team to deliver high-quality regulatory solutions to help pharmaceutical and biotech companies develop safe and efficacious medicines for patients.
Whatever your needs, we are your trusted life sciences partner:
- Ad-hoc or complex development services such as regulatory due diligence, paediatric development or orphan designation if you are developing medicines for rare diseases.
- Short-term (3–6 months), discrete projects to address a particular need for resources or expertise.
- Long-term (12–24 months) projects, such as an MAA, new drug application or biologics license application.
